The clinical trial sponsored by Shanxi Bethune Hospital aims to evaluate the safety and feasibility of umbilical cord blood-supported haploidentical hematopoietic stem cell transplantation (haplo-HSCT) for treating aplastic anemia (AA). Given the annual incidence of AA at approximately 0.74 per 100,000, the market for treatments is relatively niche but critical, particularly as current treatment options are limited and often dependent on donor availability. The study's focus on improving outcomes through innovative transplantation methods could position it favorably against existing therapies, potentially enhancing patient access to effective treatments. The results may also attract interest from pharmaceutical companies looking to expand their hematology portfolios, especially in regions with high unmet medical needs. The trial is currently recruiting, with an estimated enrollment of 110 patients, indicating a proactive approach to addressing this rare condition.